These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17538154)

  • 1. Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
    Iurisci I; Rich T; Lévi F; Innominato PF; Tinari N; Irtelli L; De Tursi M; Grassadonia A; Iacobelli S
    J Clin Oncol; 2007 Jun; 25(16):e17-9. PubMed ID: 17538154
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib.
    Zhang XT; Li LY; Wang SL; Mu XL; Wang MZ; Song W
    Chin Med J (Engl); 2005 Oct; 118(19):1661-4. PubMed ID: 16232354
    [No Abstract]   [Full Text] [Related]  

  • 3. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
    William WN; Gold KA; Kim ES
    Ann Oncol; 2009 Sep; 20(9):1455-1457. PubMed ID: 19704160
    [No Abstract]   [Full Text] [Related]  

  • 4. [A new medication for lung cancer].
    Krankenpfl J; 2005; 43(7-10):227. PubMed ID: 16515296
    [No Abstract]   [Full Text] [Related]  

  • 5. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
    Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
    Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.
    Hotta K; Inoue A; Kiura K; Ueoka H; Nukiwa T; Tanimoto M
    Lung Cancer; 2005 Dec; 50(3):413-5. PubMed ID: 16154232
    [No Abstract]   [Full Text] [Related]  

  • 7. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
    Reck M; Gatzemeier U
    Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].
    Shi Y; Sun Y; Ding C; Wang Z; Wang C; Wang Z; Bai C; Bai C; Feng J; Liu X; Li F; Yang Y; Shu Y; Wu M; He J; Zhang Y; Zhang S; Chen G; Luo H; Luo R; Zhou C; Zhou Y; Pang Q; Zhao H; Zhao Q; Gu A; Ling Y; Huang C; Han B; Jiao S; Jian H
    Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):397-400. PubMed ID: 26182862
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
    Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
    JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advanced lung cancer of performance status 3 successfully treated by gefitinib--a case report].
    Kambayashi T; Ishibashi O; Yanagihara K; Tanaka F; Hasegawa S; Wada H
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):223-6. PubMed ID: 14997756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gefitinib in non-small cell lung cancer].
    Nakagawa K
    Nihon Rinsho; 2004 Jul; 62(7):1312-20. PubMed ID: 15283149
    [No Abstract]   [Full Text] [Related]  

  • 12. [Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].
    Lv P; Zhou T
    Zhongguo Fei Ai Za Zhi; 2010 Mar; 13(3):247-53. PubMed ID: 20673523
    [No Abstract]   [Full Text] [Related]  

  • 13. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
    Pizzo B
    Clin J Oncol Nurs; 2004 Aug; 8(4):385-92. PubMed ID: 15354925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib for refractory advanced non-small-cell lung cancer.
    Moriguchi H; Kim TY; Sato C
    Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
    Cella D; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Heyes A; Ochs JS; Wolf MK; Kay AC; Kris MG; Natale RB
    J Clin Oncol; 2005 May; 23(13):2946-54. PubMed ID: 15699477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer.
    Garfield DH
    Lung Cancer; 2006 Nov; 54(2):259. PubMed ID: 16935393
    [No Abstract]   [Full Text] [Related]  

  • 17. Approved use of gefitinib.
    Lyle J
    Am J Health Syst Pharm; 2004 Oct; 61(19):2008; author reply 2008. PubMed ID: 15509120
    [No Abstract]   [Full Text] [Related]  

  • 18. Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
    Bearz A; Fratino L; Spazzapan S; Berretta M; Giacalone A; Simonelli C; Tirelli U
    Lung Cancer; 2007 Jan; 55(1):125-7. PubMed ID: 17064811
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
    Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L
    Chin Med J (Engl); 2006 Jan; 119(1):63-8. PubMed ID: 16454984
    [No Abstract]   [Full Text] [Related]  

  • 20. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
    Dahlberg SE; Gray RJ; Johnson BE
    J Clin Oncol; 2008 Sep; 26(26):4233-5. PubMed ID: 18779608
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.